Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT06246643 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

A Study of Continued Treatment With Regorafenib in Participants With Solid Tumors Who Have Participated in Other Bayer Studies

StatusActive, Not Recruiting
PhasePhase 2
SponsorBayer
Started
View on ClinicalTrials.gov ↗

Record History

  1. Eligibility criteria expanded, about 7 words
  2. Re-verified, no change to tracked fieldsv32
  3. Study sites revised (7)v31 See this version in full on ClinicalTrials.gov ↗
  4. Study sites revised (7)v30 See this version in full on ClinicalTrials.gov ↗
  5. 2 versions Re-verified since Apr 16, 2026, no change to tracked fieldsv28-v29
Show 26 earlier versionsHide 26 earlier versions
  1. Site details revised at 3 of 7 sitesv27
  2. 2 versions Re-verified since Jan 15, 2026, no change to tracked fieldsv25-v26
  3. Study sites revised (7)v24 See this version in full on ClinicalTrials.gov ↗
  4. 3 versions Re-verified since Sep 11, 2025, no change to tracked fieldsv21-v23
  5. Primary and study completion dates: Apr 27, 2026 to Apr 27, 2028v20
  6. Re-verified, no change to tracked fieldsv19
  7. Study sites revised (7)v18 See this version in full on ClinicalTrials.gov ↗
  8. 3 versions Re-verified since Mar 24, 2025, no change to tracked fieldsv15-v17
  9. Study sites revised (7)v14 See this version in full on ClinicalTrials.gov ↗
  10. 8 versions Re-verified since Jun 18, 2024, no change to tracked fieldsv6-v13
  11. Trial status: Recruiting to Active, Not Recruiting Study sites: 9 to 7v5 Show 1 more changeShow less
    • Study sites: 9 to 7
  12. Site details revised at 4 of 9 sitesv4
  13. Site details revised at 4 of 9 sitesv3
  14. Re-verified, no change to tracked fieldsv2
  1. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
Bayer
131 trials monitored
See 7 trials at risk
Regorafenib is an anti-cancer drug that blocks several proteins which are involved in the growth of cancer. It has been approved for different types of cancers of the digestive system and is being tested for use in some other solid tumors. Cancers that start in an organ, a muscle, or a bone form a solid tumor. This study is for participants with solid tumors who have been taking regorafenib in other Bayer studies. They can continue taking regorafenib if it is working when treatment with regorafenib in their previous study ends. The main purpose of this study is to find: * How safe is the continued treatment with regorafenib in participants with solid tumors? * How well is the continued treatment with regorafenib tolerated by participants with solid tumors? Participants will continue with the same dose of regorafenib that they were taking in their previous study as long as the treatment works for them/they want to continue the treatment/other medical conditions do not prevent them from participating in the study. For participants that are under 18 years of age, regorafenib tablets will be taken by mouth once daily for 2 weeks and repeat again after a 1-week gap. For participants that are over 18 years of age, regorafenib tablets will be taken by mouth once daily for 3 weeks and repeat again after a 1-week gap. At the start of the study, researchers will review participants' records from the previous study. During the study, researchers will use blood samples and X-rays taken from participants under the age of 18 years to check how safe regorafenib is for children. They will also monitor any medical problems that participants may have during the study. After the last dose, follow-up will be done either within 14 days when participants visit their study doctor or within 30-35 days by phone call. Both the researchers and the participants will know the dose of regorafenib the participants receive during the study.
Trial Details
NCT Number NCT06246643
Lead Sponsor Bayer
Conditions Solid Malignant Tumors
Enrollment 13 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov